KYMR — Kymera Therapeutics, Inc.
$122.60+0.07%
Last close: · regular session
Last 60 sessions
KYMR closed at $122.60 (+0.07%) on Oct 29, 2026. Float: 67.1M shares. Latest SEC filing: 8-K on Oct 29, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for KYMR in the TickerWise workspace.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 208
- Website: https://www.kymeratx.com
Latest SEC filings for KYMR
Latest KYMR news
- Kymera Therapeutics GAAP EPS of -$1.32 misses by $0.05 Read article
- Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial Read article
- Kymera Therapeutics Q3 2026 Earnings Preview Read article
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth? Read article
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) Read article
- Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.